Partnerships update-May 2022

Partnerships update-May 2022

The Partnerships team will be out in full force at the upcoming hematology and immunology congresses, aiming to meet supporters and prospects of our platforms alike.

Senior Partnerships Manager Geoff Jones recently attended the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022 in Paris, France. Geoff took meetings with current and prospective supporters of the Multiple Myeloma Hub, with the primary objective of providing updates on the platform. These included

·      a recap of the Multiple Myeloma Hub benefits, including the insight and engagement opportunities for supporters on the platform; and

·      a summary of Multiple Myeloma Hub new features, such as the learning outcome evaluation tool, interactive quizzes, and Google Translate, which enables the hub’s content to be translated into 100 different languages.

Geoff also attended a number of key sessions within both the educational program and satellite symposia. Some highlight sessions included

·      MMy life: your specialty, my world;

·      iStopMM study – the impact of nationwide screening;

·      Antibody-drug conjugates in relapsed/refractory multiple myeloma: from bench to bedside; and

·      Elevating standard of care in MM: unlocking the potential of novel BCMA combinations.

We look forward to sharing our insights and experiences at the upcoming congresses in June.


Partnerships Director, Ken Zangina, will be in Copenhagen, Denmark, for the European Alliance of Associations for Rheumatology (EULAR) congress on June 1–3. We will be spending time at this event to grow the footprint of our new immunology platform—Lupus Hub. Please reach out to Ken directly on should you wish to meet with him to discuss support of this platform.


Members of the Partnerships team will be available to meet in person on both sides of the Atlantic for the American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) congresses on June 3–7 and June 9–12, respectively. We look forward to connecting with our industry partners and contacts and providing some fantastic updates from all of SES’ hematology platforms, particularly with regard to the latest 2022 engagement statistics.

Please contact the partnerships team on should you wish to meet with the team at this event.

Supporter update

Psoriasis and Psoriatic Arthritis Hub 

As we approach the launch of this platform, we are pleased to announce UCB as a founding supporter of SES’ first IME resource within immunology. With a strong heritage in psoriasis and psoriatic arthritis, we are proud to have UCB supporting our efforts to deliver independent, evidence-based medical education addressing the unmet needs in these therapy areas. 


We are delighted to confirm that Amgen will be continuing its support of the ALL Hub. Amgen’s support of this platform has been steadfast since its inception and complements Amgen’s strong support for our Acute Leukemia Advocate Network (ALAN) patient-focused collaboration—Know ALL. Along with our existing industry partners, Pfizer and Novartis, Amgen’s sponsorship of the ALL Hub is highly valued and enables the SES team to continue delivery of the fantastic recent innovations implemented on the platform.

Bespoke educational opportunities

We are seeking grants from our existing and new industry partners to ensure that the following newly created bespoke educational initiatives have credible representation across the scope of therapies.

Beyond JAK inhibition: Novel agents for the treatment of advanced myelofibrosis

The clinical trials club is a live webinar series where one of our steering committee members is joined by a guest author/lead investigator of a relevant publication/clinical trial. Clinical trial clubs effectively support healthcare professionals in understanding what the latest news means for clinical practice. They offer the ideal solution to address a key learning gap of “suboptimal knowledge of novel therapeutic targets in MPN.”

“Sequencing of therapies in acute lymphoblastic leukemia (ALL)”

This case-based symposium will discuss the issues linked with the sequencing of therapies for B- and T-cell ALL. A panel of selected ALL Hub key opinion leaders will discuss cases related to both types of the disease. Pre- and post-case discussion will help develop viewers’ understanding of the recommended treatment algorithm in these cases and viewer interactivity with the panel will help raise confidence and competence in their management of these diseases. We are seeking support from industry stakeholders to enable the delivery of this learning initiative.

Please contact the Partnerships team on if you would like to learn more about supporting these educational initiatives.